Dobson Richard J, Mordi Ify, Danton Mark H, Walker Niki L, Walker Hamish A, Tzemos Nikolaos
Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital, Clydebank, Dunbartonshire, United Kingdom.
British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Congenit Heart Dis. 2017 Jan;12(1):58-66. doi: 10.1111/chd.12403. Epub 2016 Aug 24.
Myocardial fibrosis has been associated with poorer outcomes in tetralogy of Fallot, however only a handful of studies have assessed its significance in the current era. Our aim was to quantify the amount of late gadolinium enhancement in both the LV and RV in a contemporary cohort of adults with surgically repaired tetralogy of Fallot, and assess the relationship with adverse clinical outcomes.
Single centre cohort study SETTING: National tertiary referral center Patients: One hundred fourteen patients with surgically repaired tetralogy of Fallot with median age 29.5 years (range 17.5-64.2). Prospective follow-up for mean 2.4 years (SD 1.29).
Cardiovascular magnetic resonance was performed, and late gadolinium enhancement mass was estimated for the LV using the 5-SD remote myocardium method, and for the RV using a segmental scoring system. Cohort characterization was determined through the use of a computerized database.
Survival analysis from time of scan to first adverse event, defined as an episode of atrial arrhythmia, sustained ventricular arrhythmia, hospitalization with heart failure, or implantable cardioverter-defibrillator insertion.
Eleven patients experienced an adverse outcome in the follow-up period, although there were no deaths. LV late gadolinium enhancement was associated with adverse outcomes in a univariate model (P = .027). However, when adjusted for age at scan the significant variables included NYHA class (P = .006), peak oxygen uptake (P = .028), number of prior sternotomies (P = .044), and higher indexed RV and LV end diastolic volumes (P = .002 and P < .001), but not RV or LV late gadolinium enhancement.
Formal quantification of late gadolinium enhancement is not currently as helpful in ascertaining prognosis compared to other, more easily assessed parameters in a contemporary cohort of tetralogy of Fallot survivors, however assessment particularly of the LV holds promise for the future.
心肌纤维化与法洛四联症预后较差相关,但目前仅有少数研究评估了其在当代的意义。我们的目的是量化当代接受法洛四联症手术修复的成年人群体左心室和右心室晚期钆增强的量,并评估其与不良临床结局的关系。
单中心队列研究
国家三级转诊中心
114例接受法洛四联症手术修复的患者,中位年龄29.5岁(范围17.5 - 64.2岁)。前瞻性随访平均2.4年(标准差1.29)。
进行心血管磁共振成像,使用5标准差远心肌方法估计左心室晚期钆增强量,使用节段评分系统估计右心室晚期钆增强量。通过计算机数据库进行队列特征分析。
从扫描时间到首次不良事件的生存分析,不良事件定义为房性心律失常、持续性室性心律失常、因心力衰竭住院或植入心脏复律除颤器。
11例患者在随访期间出现不良结局,但无死亡病例。在单变量模型中,左心室晚期钆增强与不良结局相关(P = 0.027)。然而,在对扫描时的年龄进行校正后,显著变量包括纽约心脏协会(NYHA)分级(P = 0.006)、峰值摄氧量(P = 0.028)、既往胸骨切开术次数(P = 0.044)以及较高的右心室和左心室指数舒张末期容积(P = 0.002和P < 0.001),但不包括右心室或左心室晚期钆增强。
与当代法洛四联症幸存者队列中其他更容易评估的参数相比,目前晚期钆增强的正式量化在确定预后方面帮助不大,不过对左心室的评估在未来有一定前景。